This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Northwest Bio To Present At Society Of Neuro-Oncology Annual Meeting

BETHESDA, Md., Nov. 15, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) today announced that it will participate in the annual meeting of the Society of Neuro-Oncology (SNO) to be held at the Hyatt Regency, Orange County, California from November 17-20.  SNO is the premier professional society comprising neuro-oncologists from across the U.S. and abroad.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Company's program will include a presentation on its DCVax®-L cancer vaccine, a breakfast meeting with physicians who are current and potential investigators (i.e., lead participants at clinical trial sites), as well as other medical personnel, in the Company's ongoing Phase II clinical trial in GBM brain cancer, and an exhibit booth for any physicians or attendees interested in learning more about the DCVax results to date and progress moving forward.

The presentation on Saturday, November 19, 2011, will be at the symposium "Current State Of The Art:  Vaccine Development In The Treatment of GBM."  It will be held at 12 noon in the Grand Ballroom of the Hyatt.  Dr. Anthony Maida will review the encouraging prior clinical data for DCVax, and discuss the ongoing 240-patient trial in newly diagnosed GBM, the most lethal form of brain cancer.  This Phase II clinical trial is a randomized, double blind, placebo controlled trial currently underway at 19 clinical sites across the US, with further sites in the process of being added.

On Saturday, November 19, 2011 at 8:00 a.m., the Company will host a unique private meeting for current and potential clinical trial site doctors, nurses and other interested medical personnel concerning the Company's ongoing GBM clinical trial. The objective of this meeting will be to update current or pending sites about all aspects of this clinical trial program, as well as answer questions from potential sites that may want to participate in the future.  Newly interested parties will be asked to execute a Confidentiality Agreement.  Open and active trial sites are listed on the U.S. Government's website, www.clinicaltrials.gov, and on Northwest Bio's website at www.nwbio.com.

Finally, Northwest Bio also will host an exhibit booth in the Hyatt's Exposition Hall for the full duration of the Conference.  Information about Northwest Bio, its multiple product candidates for solid tumors,  its pipeline of INDs cleared by the FDA for clinical trials in multiple cancers, its prior clinical trial data and other information, including the process for participation in the Company's clinical trials, all will be presented by Company representatives.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs